Methotrexate is a prescription antimetabolite used to treat certain cancers, rheumatoid arthritis, psoriasis, and other autoimmune conditions. It is not a controlled substance under federal law, and it is not one of the drug classes that a standard employment drug test panel is built to detect. Employees on methotrexate therapy, and the employers who manage drug free workplace programs, often want to know whether the medication could affect a screening result or create confusion during a workplace test. This article explains what workplace panels actually screen for, what the science says about methotrexate and cross reactivity, and why the medical review officer process exists for exactly this kind of question.
Nothing here is medical or legal advice. Employees with questions about a specific prescription should talk to the prescribing clinician, and employers with policy questions should talk to counsel or their medical review officer.
What methotrexate is used for
Methotrexate works by interfering with folate metabolism, which slows the growth of rapidly dividing cells. At the higher doses used in oncology it is a chemotherapy agent. At the much lower, weekly doses used in rheumatology and dermatology it is a disease modifying antirheumatic drug (DMARD) prescribed for rheumatoid arthritis, psoriatic arthritis, and psoriasis, among other conditions. The drug label and prescribing information, maintained in the National Library of Medicine's DailyMed database, lists its approved uses, warnings, and drug interactions in detail, and that label does not identify any interaction with urine drug screening immunoassays because the two are unrelated testing systems measuring different things for different reasons.
Methotrexate is not scheduled under the federal Controlled Substances Act, and it carries no recognized misuse or diversion profile that would place it on an employer's drug testing menu.
What a standard workplace drug test panel actually screens for
Workplace urine drug testing programs, including the federal model that the Substance Abuse and Mental Health Services Administration (SAMHSA) sets for federally regulated and many private sector programs, are built around a defined list of drug classes. The federal panel historically covers amphetamines, cocaine metabolites, marijuana metabolite (THC), opiates, and phencyclidine (PCP), and many employer panels expand that list to include benzodiazepines, barbiturates, methadone, and propoxyphene. SAMHSA's workplace drug testing program pages describe the mandatory guidelines that define these panels and the laboratories certified to run them.
For transportation employees subject to Department of Transportation testing, the regulation that defines the drugs and drug metabolites a laboratory must test for is published in the Code of Federal Regulations, 49 CFR 40.85. Methotrexate, an antifolate chemotherapy and rheumatology drug, does not appear on that list and is structurally unrelated to any drug class the panel targets.
Screening immunoassay versus confirmation testing
It helps to separate the two steps in a typical workplace drug test. The first step is an immunoassay screen, a fast chemical test that uses antibodies designed to bind to a target drug class. Immunoassays are efficient but not perfectly specific, and they can occasionally bind to a compound that is chemically similar to the target drug, producing a nonnegative screening result that is not a confirmed positive. The second step, used whenever a screen comes back nonnegative, is laboratory confirmation by gas chromatography mass spectrometry (GC/MS) or liquid chromatography mass spectrometry (LC/MS). These confirmation methods identify the exact molecule present, rather than a class of molecules, which is why a confirmed result is far more specific than a screening result.
Cross reactivity happens when a medication shares enough chemical structure with the antibody's target to trigger a nonnegative screen. Methotrexate's antifolate structure has no meaningful similarity to amphetamines, opiates, cocaine metabolites, PCP, or THC, which is the structural reason no published cross reactivity with standard employment immunoassay panels has been documented for this drug.
Is there documented cross reactivity for methotrexate?
Based on the current DailyMed prescribing information and the National Library of Medicine's consumer drug reference for methotrexate, there is no published cross reactivity between methotrexate and the standard amphetamine, opiate, cocaine, PCP, or THC immunoassay panels used in employment testing. Reporting on this should be precise rather than absolute: the honest statement is that there is no published cross reactivity in the literature that American Screening Corporation could verify, not that cross reactivity is scientifically impossible in every laboratory's proprietary assay formulation. Any employee who tests nonnegative while taking methotrexate, for whatever reason, should expect the result to route to confirmation testing and a medical review officer rather than being reported to the employer as positive without review.
The methotrexate blood level test is a different test entirely
Patients receiving methotrexate, particularly at chemotherapy doses, are often monitored with a blood methotrexate level test. This is a clinical lab test that measures the concentration of the drug itself in the bloodstream over time, used by the treating physician to watch for delayed clearance and toxicity risk. It has nothing to do with a workplace urine drug screen. A workplace test looks for drugs of abuse in urine or oral fluid using immunoassay and confirmation methods described above; a methotrexate level test looks for methotrexate itself in blood as part of ongoing medical care. Confusing the two can lead to unnecessary worry. Neither this article nor any screening program should be read as offering guidance on how that clinical monitoring should be interpreted; that is between the patient and the treating clinician.
Common immunosuppressant and rheumatology drugs and workplace panels
| Medication | Typical use | Controlled substance | Standard panel target | Notes |
|---|---|---|---|---|
| Methotrexate | Rheumatoid arthritis, psoriasis, certain cancers | No | No | No published cross reactivity with standard immunoassay panels |
| Hydroxychloroquine | Rheumatoid arthritis, lupus | No | No | Antimalarial derivative, not a panel target |
| Sulfasalazine | Rheumatoid arthritis, inflammatory bowel disease | No | No | Sulfa based DMARD, not a panel target |
| Leflunomide | Rheumatoid arthritis | No | No | Pyrimidine synthesis inhibitor, not a panel target |
| Azathioprine | Autoimmune disease, transplant immunosuppression | No | No | Purine analog, not a panel target |
| Cyclosporine or tacrolimus | Transplant immunosuppression | No | No | Calcineurin inhibitors, not a panel target |
| Adalimumab and other biologic DMARDs | Rheumatoid arthritis, psoriasis, psoriatic arthritis | No | No | Injectable monoclonal antibodies, not detected by urine or oral fluid drug panels at all |
None of the medications in this table are controlled substances, and none are listed targets on the standard SAMHSA style panels used in most workplace programs. This table describes typical program design and is not a substitute for checking the specific panel and cutoffs a given employer or laboratory uses.
The ADA angle: what an employer can ask about medication
The Americans with Disabilities Act limits when and how an employer can ask an employee about prescription medication, because that question can reveal information about a disability. The Equal Employment Opportunity Commission's guidance on disability related inquiries explains that employers generally may not ask broad questions about what medications an employee takes outside of specific, job related, and consistent with business necessity circumstances, and that medical information gathered through a drug testing or MRO process has confidentiality protections. Employers should rely on counsel to apply this guidance to a specific testing policy rather than treating any summary, including this one, as a legal determination.
The medical review officer process and prescription documentation
This is exactly the situation the medical review officer (MRO) role exists to handle. When a screening immunoassay comes back nonnegative, a certified MRO, a licensed physician trained in this review, contacts the employee confidentially before any result reaches the employer. The employee can provide a valid prescription and other documentation, and the MRO determines whether a legitimate medical explanation accounts for the result. For a drug like methotrexate, which is not a panel target to begin with, a nonnegative result is unlikely for that reason, but the MRO review step still applies to any unusual or disputed result, and it is the proper channel for an employee to raise a prescription rather than disputing a result directly with a supervisor. Our site has a full explanation of how that review works at the medical review officer process page.
Employees taking any prescription medication, methotrexate included, should keep current prescription documentation available and disclose it to the MRO if asked, rather than to a supervisor or coworker. That keeps protected health information inside the confidential MRO channel where it belongs.
What employers should do
Employers running a drug free workplace program should confirm with their laboratory and MRO which drug classes their panel actually screens, since panels vary by employer and by industry. Programs should never report a screening result to management before MRO review is complete, and policies should describe the MRO review and appeal path clearly so employees know where to bring a prescription. No test, immunoassay or confirmation, should be described as promised or complete, and no screening product should be called approved by the Food and Drug Administration; device clearance language should track exactly what the manufacturer's labeling states. For background on prescription drugs that genuinely do show documented cross reactivity with specific panels, our post on clonidine and workplace panels walks through a case where MRO review matters for a different reason. Employers sourcing cups, dip cards, or oral fluid devices for an in house program can review current panel configurations at the drug test cup collection.
Frequently asked questions
Does methotrexate show up on a standard drug test panel?
No. Methotrexate is not a controlled substance and is not one of the drug classes that standard SAMHSA style or DOT panels are designed to detect, and there is no published cross reactivity with those immunoassays.
Can methotrexate cause a false positive on an immunoassay screen?
There is no published evidence of methotrexate cross reacting with amphetamine, opiate, cocaine, PCP, or THC immunoassays. Any nonnegative screening result for an unrelated reason should still go through confirmation testing and medical review officer review before being treated as positive.
Is a methotrexate blood level test the same as a drug test?
No. A methotrexate level test is a clinical blood test used by a treating physician to monitor drug clearance and toxicity risk. It is unrelated to a workplace urine or oral fluid drug of abuse screen.
Can an employer ask why an employee takes methotrexate?
Generally, broad questions about a specific prescription raise Americans with Disabilities Act concerns outside limited, job related circumstances. Prescription disclosure in a testing context should go through the confidential medical review officer channel, and employers should rely on counsel for policy specifics.
What should an employee on methotrexate do before a workplace drug test?
Keep current prescription documentation available and be ready to provide it to the medical review officer if contacted about any nonnegative result. There is no need to disclose medication to a supervisor to comply with a standard panel.
Do other rheumatoid arthritis or immunosuppressant drugs show up on panels?
Common DMARDs and biologics such as hydroxychloroquine, sulfasalazine, leflunomide, azathioprine, and adalimumab are not controlled substances and are not standard panel targets, the same as methotrexate.
This article is general information about drug testing science and workplace programs, not medical or legal advice. Employees should direct medical questions to their prescribing clinician and disclose prescriptions through a medical review officer. Employers should direct policy and compliance questions to qualified counsel.